Compare OPTT & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPTT | BMEA |
|---|---|---|
| Founded | 1984 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.9M | 90.5M |
| IPO Year | 2006 | 2021 |
| Metric | OPTT | BMEA |
|---|---|---|
| Price | $0.33 | $1.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $1.50 | ★ $8.71 |
| AVG Volume (30 Days) | ★ 6.9M | 1.1M |
| Earning Date | 03-17-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 63.83 | ★ 69.19 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,861,000.00 | N/A |
| Revenue This Year | $39.58 | N/A |
| Revenue Next Year | $168.27 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.08 | N/A |
| 52 Week Low | $0.29 | $0.87 |
| 52 Week High | $0.90 | $3.07 |
| Indicator | OPTT | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 37.22 | 51.19 |
| Support Level | $0.30 | $1.22 |
| Resistance Level | $0.56 | $1.47 |
| Average True Range (ATR) | 0.04 | 0.11 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 3.22 | 50.56 |
Ocean Power Technologies Inc provides intelligent maritime solutions and services that enable safer, cleaner, and more productive ocean operations for the defense and security, oil and gas, science and research, and offshore wind markets. It provides ocean data collection and reporting, marine power, offshore communications, and Maritime Domain Awareness System (MDAS) products, integrated solutions, and consulting services. The company offers its products and services to a wide range of customers, including those in government and offshore energy, oil and gas, construction, wind power, and other industries. The company has operations in North and South America, Europe, Asia and Australia.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.